Superiority of low dose benzbromarone add-on to low dose febuxostat compared to febuxostat monotherapy in gout with combined-type hyperuricemia.

Simply adding on low-dose benzbromarone (25 mg/day) to low-dose (20 mg/day) febuxostat showed superior urate lowering to febuxostat monotherapy in gout with a combined-type hyperuricemia. For selected patients, expedited achievement of serum urate target in over 75% of subjects, using one titration step and low XOI and uricosuric doses, is a potential alternative to standard ULT regimens. This article is protected by copyright. All rights reserved.